

High expression of *RUNX1* is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia

Lin Fu^{1,*}, Huaping Fu^{3,*}, Lei Tian^{1,*}, Keman Xu⁴, Kai Hu¹, Jing Wang¹, Jijun Wang¹, Hongmei Jing¹, Jinlong Shi², Xiaoyan Ke¹

¹Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, 100191, China

²Medical Engineering Support Center, Chinese PLA General Hospital, Beijing, 100853, China

³Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing, 100853, China

⁴College of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, 163319, China

*These authors contributed equally to this work

Correspondence to: Jinlong Shi, e-mail: jinlong_301@163.com
Xiaoyan Ke, e-mail: xiaoyank@yahoo.com

Keywords: *RUNX1*, prognostic biomarker, CN-AML

Received: October 15, 2015

Accepted: January 24, 2016

Published: February 19, 2016

ABSTRACT

Depending on its expression level, *RUNX1* can act as a tumor promoter or suppressor in hematological malignancies. The clinical impact of *RUNX1* expression in cytogenetically normal acute myeloid leukemia (CN-AML) remained unknown, however. We evaluated the prognostic significance of *RUNX1* expression using several public microarray datasets. In the testing group ($n = 157$), high *RUNX1* expression (*RUNX1*^{high}) was associated with poorer overall survival (OS; $P = 0.0025$) and event-free survival (EFS; $P = 0.0025$) than low *RUNX1* expression (*RUNX1*^{low}). In addition, the prognostic significance of *RUNX1* was confirmed using European Leukemia Net (ELN) genetic categories and multivariable analysis, which was further validated using a second independent CN-AML cohort ($n = 162$, OS; $P = 0.03953$). To better understand the mechanisms of *RUNX1*, we investigated genome-wide gene/microRNAs expression signatures and cell signaling pathways associated with *RUNX1* expression status. Several known oncogenes/oncogenic microRNAs and cell signaling pathways were all up-regulated, while some anti-oncogenes and molecules of immune activation were down-regulated in *RUNX1*^{high} CN-AML patients. These findings suggest *RUNX1*^{high} is a prognostic biomarker of unfavorable outcome in CN-AML, which is supported by the distinctive gene/microRNA signatures and cell signaling pathways.

INTRODUCTION

Cytogenetically normal acute myeloid leukemia (CN-AML) comprises the largest percentage of primary AML cases [1]. Although the leukemic blasts do not include detectable chromosome abnormalities in CN-AML patients, they nonetheless hide mutations and aberrantly expressed proteins [2] and microRNAs [3], which are potentially prognostic. Among them, *NPM1* [4] and double *CEBPA* [5] mutations are associated with better outcomes, while *FLT3*-ITD [6] and *RUNX1* mutation [7] are associated with poorer ones. High expression of *WT1* [8], *BAALC* [9], *ERG* [9], *MNI* [10], *DNMT3B* [11], *TCF4* [12], *ITPR2* [13] and *MAPKBPI* [14] and low expression of *LEF1* [15] are also associated with a poor prognosis, as

is high expression of *miR-155* [16] and *miR-188-5p* [17] and low expression of *let-7a-2-3p* [17].

RUNX1 belongs to the Runt-related transcription factor (*RUNX*) family, which plays a crucial role in normal hematopoiesis, and its abnormal expression is frequently seen in various tumors [18, 19]. In several AML subtypes, for example, chromosomal translocations involving *RUNX1* lead to fusion gene formation, *RUNX1-RUNX1TI* being the most common type [20]. In addition, *RUNX1* mutation leads to a poor outcome in CN-AML [7], and high expression of *RUNX1* correlates with a poor prognosis in breast cancer [21]. Notably, although early studies suggested *RUNX1* acts as a tumor suppressor gene in AML [22], it is now understood that *RUNX1* functions as an oncogene necessary to sustain AML [23–26]. These

findings suggest that the prognostic impact of *RUNX1* in CN-AML depends on its expression level.

We found that *RUNX1* is more strongly expressed in CN-AML patients than in normal bone marrow (NBM), but also was an unfavorable prognostic factor in two large, independent groups of patients with CN-AML. In addition, we provide the first report that *RUNX1* expression is linked to particular molecular and clinical characteristics. In order to cast light on the function of *RUNX1*, we also explored *RUNX1*-associated genes, microRNAs and important cell signaling pathways.

RESULTS

Expression of *RUNX1* in CN-AML BM and NBM

A microarray dataset that included 116 CN-AML samples and 5 NBM samples (GEO accession number *GSE1159*) was used for the expression analysis [27]. *RUNX1* expression was markedly higher in the CN-AML than NBM samples ($P < 0.001$) (Figure 1A). The overexpression of *RUNX1* in CN-AML was further validated using other microarray data, which included 9 CN-AML vs. 10 NBM ($P < 0.001$) and 9 CN-AML vs. 10 normal peripheral blood (NPB) ($P < 0.001$). The 9 CN-AML samples consisted of 2 BM and 7 PB samples, GEO accession number *GSE9476* [28] (Figure 1B). These

findings show that *RUNX1* overexpression is widespread among CN-AML patients, and is easy to monitor.

Characteristics of patients in the *RUNX1*^{high} and *RUNX1*^{low} expression groups

Among the 157 CN-AML patients tested, the *RUNX1*^{high} group contained significantly more patients with FAB M2 than the *RUNX1*^{low} ($P = 0.001$). The *RUNX1*^{high} patients were also more likely than *RUNX1*^{low} patients to carry *FLT3*-ITD and no double *CEBPA* mutations ($P < 0.001$, $P = 0.003$). We found no link between *RUNX1* expression and other gene mutations, but *RUNX1*^{high} patients with CN-AML were more likely to highly express *ERG*, *WT1*, *DNMT3B*, *TCF4*, *MIR155HG*, *ITPR2* and *MAPKBPI* ($P < 0.001$, $P < 0.001$, $P < 0.001$, $P < 0.001$, $P = 0.01$, $P < 0.001$, and $P < 0.001$, respectively) (Table 1, Supplementary Figure 1).

RUNX1^{high} is associated with poor outcomes

The median overall survival (OS) and event-free survival (EFS) in the *RUNX1*^{high} group were obviously poorer than that of *RUNX1*^{low} group ($P = 0.009$, $P = 0.011$, respectively, Table 2). This was confirmed comparison using the Log-rank test, which also showed that OS (Figure 2B, $P = 0.0025$) and EFS (Figure 2A, $P = 0.0025$) were clearly poorer in the *RUNX1*^{high} than *RUNX1*^{low} group.




Figure 1: Expression of *RUNX1* in CN-AML patients and NBM. (A) Box plot of *RUNX1* expression in CN-AML patients ($n = 116$) and NBM samples ($n = 5$). (B) Box plot of *RUNX1* expression in CN-AML patients ($n = 9$, including 2 BM and 7 PB samples), NBM samples ($n = 10$) and NPB samples ($n = 10$).

Table 1: Patients' characteristics in the testing group of 157 CN-AML patients according to *RUNX1* expression levels

Variable	<i>RUNX1</i> ^{high} , n = 78	<i>RUNX1</i> ^{low} , n = 79	P
Median age. y (range)	50 (18~77)	48 (16~75)	0.325
Female sex, no.(%)	40	33	0.27
FAB subtype, no.			
M0	1	2	1
M1	25	20	0.38
M2	24	8	0.001
M3	1	0	1
M4	12	12	0.5
M5	14	25	0.06
M6	0	1	1
Other	1	11	0.005
<i>FLT3</i> -ITD, no.	45	21	< 0.001
<i>FLT3</i> -TKD, no.	8	12	0.47
<i>NPM1</i> , mutated, no.	46	36	0.11
Double <i>CEBPA</i> , mutated, no.	2	14	0.003
<i>N-RAS</i> , mutated, no.	4	9	0.25
<i>K-RAS</i> , mutated, no.	0	1	1
<i>IDH1</i> , mutated, no.	58	59	0.64
<i>IDH2</i> , mutated, no.	59	64	0.49
ELN genetic group, no.			
Favorable	13	22	0.125
Intermediate-I	65	57	0.12
High <i>ERG</i> , no.	51	27	< 0.001
High <i>BAALC</i> , no.	43	35	0.2
High <i>LEF1</i> , no.	33	45	0.08
High <i>MNI</i> , no.	39	39	1
High <i>WT1</i> , no.	60	18	< 0.001
High <i>DNMT3B</i> , no.	58	20	< 0.001
High <i>TCF4</i> , no.	53	25	< 0.001
High <i>MIR155HG</i> , no.	47	31	0.01
High <i>ITPR2</i> , no.	54	24	< 0.001
High <i>MAPKBPI</i> , no.	54	24	< 0.001

FAB, French-American-British classification; **ITD**, internal tandem duplication; **TKD**, tyrosine kinase domain; **ELN**, European Leukemia Net.

High *ERG*, *BAALC*, *LEF1*, *MNI*, *WT1*, *DNMT3B*, *TCF4*, *MIR155HG*, *ITPR2* and *MAPKBPI* expression were defined as an expression level above the median of all samples, respectively.

Association of *RUNX1* expression with prognostic significance in ELN genetic groups

We assessed the association between *RUNX1* expression and prognostic significance separately within the European Leukemia NET (ELN) favorable and Intermediate-I genetic groups. Within the ELN favorable group ($n = 35$), there was no obvious difference in OS

(Figure 3A, $P = 0.6976$) and EFS (Figure 3B, $P = 0.5098$) between the *RUNX1*^{high} and *RUNX1*^{low} group. In the ELN Intermediate-I group ($n = 122$), however, the *RUNX1*^{high} group had poorer OS (Figure 3C, $P = 0.0009$) and EFS (Figure 3D, $P = 0.0014$) than the *RUNX1*^{low} group. The median OS, EFS and estimated survival in the ELN Intermediate-I group ($n = 122$) also obviously differed between the *RUNX1*^{high} and *RUNX1*^{low} groups (Table 2).

Table 2: Survival according to *RUNXI* expression in the testing group of 157 CN-AML patients

Outcome	All patients, n = 157			ELN Favorable category			ELN Intermediate-I category		
	<i>RUNXI</i> ^{high} , n = 78	<i>RUNXI</i> ^{low} , n = 79	P	<i>RUNXI</i> ^{high} , n = 17	<i>RUNXI</i> ^{low} , n = 18	P	<i>RUNXI</i> ^{high} , n = 65	<i>RUNXI</i> ^{low} , n = 57	P
OS									
Median OS, m	10.46 (0.07–198.7)	37.03 (0.13–214.5)	0.009	58.91 (0.59–169.5)	38.34 (0.3–214.5)	0.65	8.41 (0.07–198.7)	35.91 (0.13–190.3)	0.002
Estimated OS at 3 y. % (95% CI)	0.33 (0.24–0.46)	0.54 (0.45–0.67)	0.01	0.65 (0.46–0.92)	0.56 (0.37–0.84)	0.73	0.25 (0.16–0.38)	0.54 (0.43–0.68)	0.007
EFS									
Median EFS, m	7.1 (0.03–198.7)	17.81 (0.03–214.5)	0.011	39.82 (0.03–169.5)	33.03 (0.03–214.5)	0.36	6.57 (0.03–198.7)	15.54 (0.03–190.3)	0.004
Estimated EFS at 3 y. % (95% CI)	0.28 (0.2–0.4)	0.41 (0.31–0.53)	0.005	0.53 (0.34–0.83)	0.56 (0.37–0.84)	0.17	0.2 (0.12–0.33)	0.38 (0.27–0.52)	0.03

CI, confidence interval.

***RUNXI* expression is associated with poorer OS and EFS in multivariable analyses**

ELN segregated CN-AML patients based on presence of *FLT3*-ITD, mutations of *NPM1* and *CEBPA*. After adjusting for the impact of these known risk factors, we performed multivariable analyses to confirm the prognostic significance of *RUNXI* expression. In a multivariable model, the *RUNXI*^{high} group had a poorer OS ($P = 0.04$, Table 3). The other factors associated with poor OS were *NPM1* wild-type and *FLT3*-ITD. The *RUNXI*^{high} group also had a poorer EFS in a multivariable model ($P = 0.02$, Table 3). The other factors associated with poor EFS were *NPM1* wild-type and *FLT3*-ITD.

Validation in a patient group of 162 CN-AML samples

We also studied a group of 162 previously untreated CN-AML patients. The *RUNXI*^{high} group contained significantly more patients with FAB M1 than the *RUNXI*^{low} group ($P = 0.0014$). In addition, *RUNXI*^{high} patients with CN-AML were more likely to have higher expression of *ERG*, *BAALC*, *WT1*, *DNMT3B*, *TCF4*, *ITPR2* and *MAPKBP1* ($P < 0.001$, $P = 0.028$, $P < 0.001$, $P < 0.001$, $P < 0.001$, $P < 0.001$, and $P < 0.001$, respectively) and low *LEF1* ($P < 0.001$) compared with *RUNXI*^{low} patients (Supplementary Table 1). In addition, *RUNXI*^{high} patients showed a significant poor OS ($n = 81$




Figure 2: *RUNXI*^{high} is associated with poorer outcomes. (A) OS and (B) EFS in the testing group of 157 CN-AML patients.

vs $n = 81$, $P = 0.04$; Supplementary Figure 2) than $RUNX1^{low}$ patients.

Genome-wide gene expression profiles associated with $RUNX1$ expression

To further evaluate the role of $RUNX1$ in CN-AML, we using microarray analysis to determine $RUNX1$ -associated gene expression profiles. We identified 578 up-regulated genes and 727 down-regulated genes that were significantly associated with $RUNX1^{high}$ (Supplementary Table 2). The up-regulated genes included some of those previously found to be involved in leukemogenesis, including $CDK6$, which encodes a cyclin kinase; $MYCN$, MYB and MYC ; members of the $HOXB$ gene family ($HOXB2$, $HOXB3$, and $HOXB4$), which encode transcription factors [29]; and $c-KIT$ and $FLT3$, which encode tyrosine kinases. Several independent unfavorable prognostic factors in CN-AML were also up-regulated, including ERG , $WT1$, $TCF4$ and $DNMT3B$. Also up-regulated were $B4GALT6$, which is expressed in less differentiated precursors [30]; $SOCS2$, which

is predictive of a poor outcome in pediatric AML [31]; $BCL11A$ and $GUCY1A3$, which are down-regulated in low ERG expressers [9]; $GTF2H2/ABCC5$, which correlates with chemotherapy resistance in non-small cell lung cancer [32]; $DNMT1$, which is expressed in early lymphoid precursors [33]; $CD109$, which is overexpressed in early hematopoietic stem cells [34]; $FAM92A1$, which enhances cell growth during renal carcinogenesis [35]; and $MMP2$, which promotes lung cancer metastasis [36]. The down-regulated genes included thanatos-associated protein 2 ($THAP2$) and $CD48$, $CD86$ and $ICAM1$, all of which are involved in immune function. $LEF1$, an independent favorable prognostic factor in CN-AML, was also down-regulated (Figure 4A and 4B). These results provided further evidence for the prognostic correlation described above.

Genome-wide microRNA profiles associated with $RUNX1$ expression

A genome-wide analysis of microRNA profiles revealed that 108 microRNAs were significantly associated with $RUNX1$ expression ($P < 0.05$)




Figure 3: Association of $RUNX1$ expression with the prognostic significance in ELN genetic groups. (A) OS and (B) EFS of CN-AML patients in the ELN favorable genetic group. (C) OS and (D) EFS of CN-AML patients in the ELN intermediate-I genetic group.

Table 3: Multivariable analysis with OS and EFS in the testing group of 157 CN-AML patients

Variable	OS, n = 157		EFS, n = 157	
	HR (95% CI)	P	HR (95% CI)	P
<i>RUNX1</i> expression, high VS low	1.56 (1.01–2.41)	0.04	1.65 (1.10–2.48)	0.02
Age, per 10-y increase	1.13 (0.98–1.32)	0.09	1.05 (0.92–1.21)	0.47
Sex male VS female	0.82 (0.54–1.23)	0.33	0.99 (0.67–1.46)	0.96
NPM1, mutated VS wild type	0.51 (0.32–0.81)	0.005	0.53 (0.34–0.83)	0.005
FLT3-ITD, mutated VS wild type	1.98 (1.25–3.14)	0.003	1.85 (1.20–2.85)	0.005
CEBPA, mutated VS wild type	0.71 (0.38–1.35)	0.3	0.78 (0.43–1.41)	0.41

HR, hazards ratio; CI, confidence interval.

(Supplementary Table 3). *RUNX1*^{high} was positively associated with *miR-155*, *miR-125a*, *miR-99b*, *miR-133a*, *miR-130a*, *miR-25* and *miR-92a-1*. *MiR-155* was previously found to function as an oncogene in CN-AML [16]. *MiR-125a* and *miR-99b* were highly expressed in hematopoietic stem cells [37]. *MiR-133a* was up-regulated in CN-AML along with *IDH2* codon R172K [38]. *MiR-130a* associated with strong expression of *WT1*, which was consistent with the gene-expression profiles [39]. *MiR-25* increases induction of somatic cells into induced pluripotent stem cells [40]. *MiR-92a-1* arouses erythroleukemia through down-regulation of *p53* [41]. Notably, *miR-193a*, *miR-107* and *miR-212* were all down-regulated. We previously found that *miR-193a* enhanced expression of *c-kit* [42], which is also consistent with the observed gene-expression profiles. *MiR-107* targets *NFIX*, which competes with *CEBPA* for binding to the promoter of *miR-223*, impaired granulocytic differentiation [43, 44]. *MiR-212* expression is favorable for survival among molecularly and cytogenetically heterogeneous AMLs [45] (Figure 4C and 4D).

Genome-wide methylation profiling associated with *RUNX1* expression

It has been suggested that control of gene expression through methylation of the gene promoter or body plays a pivotal role in determining the behavior of cancer cells [46, 47]. Moreover, gene promoter methylation can be predictive of clinical outcome in AML patients [48, 49]. Because *RUNX1* expression correlated positively with *DNMT3B* expression, we compared the patterns of gene methylation in *RUNX1*^{high} (*n* = 37) and *RUNX1*^{low} (*n* = 37) CN-AML from TCGA [50]. However, we found no significant differences in patterns of *RUNX1* methylation in any of these analyses (Supplementary Figure 3A and 3B).

Cell signaling pathways associated with *RUNX1* expression

We used MSigDB [51] to evaluate the cell signaling pathways underlying the biological features associated with *RUNX1*. Signaling pathways involved

in *DNA_REPLICATION*, *RNA_POLYMERASE* and *CELL_CYCLE* were significantly up-regulated, while *NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY*, *ANTIGEN_PROCESSING_AND_PRESENTATION* and *APOPTOSIS* were down-regulated (Table 4). These findings were consistent with the above-noted dysregulated genes involved in the development of CN-AML.

DISCUSSION

CN-AML is the largest cytogenetic subset in AML patients and lacks sensitive prognostic biomarkers, so identification of universal prognostic biomarkers is a very important field in CN-AML research. *RUNX1* plays a crucial role in the development of normal hematopoiesis. Traditionally, loss of *RUNX1* leads to impaired differentiation and is followed by leukemia development [52]. However, several recent studies found that *RUNX1* plays a prosurvival role by supporting leukemia cell proliferation [23–26]. Based on earlier studies of *RUNX1*, the following conclusions can be made: 1) *RUNX1* plays an important dual role in myeloid leukemogenesis, depending on the level of its expression; 2) normal expression of *RUNX1* works as a tumor suppressor, inhibiting cell proliferation and promoting differentiation of hematopoietic progenitor cells; 3) Partial deactivation of *RUNX1* leads to amplification of myeloid progenitors and subsequent development of AML; and 4) further reduction of *RUNX1* expression causes cell cycle arrest and cell death [23–26].

Extending the studies outlined above, ours is the first study to show the prognostic relevance of *RUNX1* expression in CN-AML patients and that *RUNX1*^{high} is associated with poorer OS and EFS in CN-AML patients. *RUNX1* is up-regulated in CN-AML patients compared with NBM. In our study, the *RUNX1*^{high} group contained significantly more patients from the M1 (validating group) and M2 (testing group) FAB subgroups than did the *RUNX1*^{low} group, which suggests leukemic cells from *RUNX1*^{high} patients derive from relatively more immature cells. In addition, we found that *RUNX1*^{high} was associated with *FLT3-ITD*, non double *CEBPA* mutation and higher *ERG*, *WT1*, *DNMT3B*, *TCF4*,

MIR155HG, *ITPR2*, *MAPKBPI* expression, all of which are unfavorable molecular characteristics in CN-AML patients. Furthermore, the association of *RUNX1*^{high} with poorer OS and EFS was confirmed in multivariable analyses adjusting for the most important clinical and molecular prognosticators in CN-AML patients. *RUNX1*^{high} was associated with wild-type *NPM1* and *FLT3-ITD*, both of which are unfavorable molecular characteristics in CN-AML patients. These results suggest *RUNX1*^{high} may be a surrogate marker for other unfavorable mutations. Our results also suggest that the prognostic impact of *RUNX1* expression is most pronounced in the ELN intermediate-I genetic group, and thus *RUNX1* expression may be used to further refine risk stratification for these patients.

The mechanisms underlying the association between *RUNX1*^{high} and poorer treatment outcomes are unclear. In our present study, we analyzed gene and microRNA expression, DNA methylation profiles, and cell signaling pathways to identify biological mechanisms associated with *RUNX1* expression in CN-AML patients. Gene sets related to cell proliferation and cell cycle regulation, particularly *c-KIT*, *FLT3*, *MYCN*, *MYB*, *MYC*

and *CDK6*, were up-regulated in the CN-AML patients with *RUNX1*^{high}, while gene sets related to independent unfavorable prognostic factors, particularly *ERG*, *WT1* and *DNMT3B*, were also up-regulated, and gene sets related to apoptosis, immune activation of NK cell and independent superior prognostic factor were down-regulated. Acting collectively, these features may lead to CN-AML.

The *RUNX1*-associated microRNA profile was also noteworthy, as it included the *miR-155* and *miR-130a* families, which were expressed with *RUNX1*. The up-regulation of *miR-155* was associated with an unfavorable clinical outcome independently in CN-AML. *MiR-130a* was associated with high expression of *WT1*. The down-regulation of *miR-193a* was associated with high expression of *c-KIT*. This new finding of *RUNX1*-associated alterations in microRNA expression may contribute to leukemogenesis.

Current studies suggest that hypermethylation of the gene promoter and hypomethylation of gene body contribute to the development of tumors [46, 47]. However, we found no significant association between *RUNX1* expression and the methylation levels in its




Figure 4: Genome-wide gene/microRNA-expression profiles associated with *RUNX1* expression. (A) Expression heat map of associated genes (B) The list of associated genes. (C) Expression heat map of associated microRNAs. (D) The list of associated microRNAs.

Table 4: Cell signalling pathways associated with *RUNX1* expression levels

Pathway name	According to high expression of <i>RUNX1</i>	
	Regulation	P
KEGG_DNA_REPLICATION	Up	0.00424
KEGG_RNA_POLYMERASE	Up	0.01575
KEGG_CELL_CYCLE	Up	0.02204
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY	Down	0.00000
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION	Down	0.00000
KEGG_APOPTOSIS	Down	0.00217

promoter region or gene body. Therefore, although *RUNX1*^{high} is a predictive marker poorer outcome in CN-AML, epigenetic regulation may not play an important role in *RUNX1*^{high} CN-AML development.

Several important signaling pathways that promote cell proliferation in tumors or contribute to leukemogenesis, including *DNA_REPLICATION*, *RNA_POLYMERASE* and *CELL_CYCLE* were up-regulated, and *NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY*, *ANTIGEN_PROCESSING_AND_PRESENTATION*, all lead to immune escape, while *APOPTOSIS* was down-regulated in the *RUNX1*^{high} CN-AML. These changes may contribute to a poor outcome.

In summary, our study is the first to provide evidence that *RUNX1*^{high} is associated with poorer outcomes in CN-AML patients, even after adjusting for known molecular risk factors. In the validating group, earlier findings demonstrated that the microarray expression data for *LEF1* was in good agreement with quantitative real time PCR (qPCR) [15]. This shows to some degree the consistency and validity of the microarray expression data. Because *RUNX1* is widely expressed at a higher level in CN-AML patients than NBM, *RUNX1* expression can be easily measured. This may therefore be a valuable new marker for risk stratification of CN-AML patients. Moreover, our gene/microRNA expression data and cell signaling pathways from tested CN-AML patients offers insight into the biological changes associated with different *RUNX1* expression levels.

MATERIALS AND METHODS

Patients and treatment

In the testing group, 157 patients with previously untreated CN-AML (median age, 50 years; range, 16–77 years) were studied. All patients received uniform therapeutic treatment based on study protocols of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) between 1990 and 2008 (The details of therapeutic protocol are available at <http://www.hovon.nl>) [53] (Supplementary Figure 4). One hundred thirty

patients (83%) were aged < 60 years (younger patients) and 27 patients (17%) were ≥ 60 years (older patients). The diagnosis of normal karyotype AML was based on conventional cytogenetic examination of at least 20 metaphases from BM. Patients were assessed for *NPM1*, *CEBPA*, *N-RAS*, *K-RAS*, *IDH1*, and *IDH2* mutations, *FLT3*-ITD, and tyrosine kinase domain mutations (*FLT3*-TKD [D835]). Clinical, cytogenetic and molecular information, as well as the gene expression profiles for all primary AML cases, can be publicly downloaded from the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo, accession number *GSE6891*) [53]. This research was approved by the institutional review boards at Weill Cornell Medical College and Erasmus University Medical Center, and written informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Another independent validation group of 162 CN-AML patients received uniform therapeutic treatment provided as part the multicenter AMLCG-1999 trial, which was used to validate our findings. These patients received intensive double induction and consolidation chemotherapy. Gene expression data are publicly available (<http://www.ncbi.nlm.nih.gov/geo/>, accession number *GSE12417*) [54]. The AMLCG-1999 clinical trials were approved by the local institutional review boards, and informed consent from all patients was obtained in accordance with the Declaration of Helsinki [54].

Microarray analyses

Gene expression and methylation data have been previously published (accession number *GSE1159* [27], *GSE9476* [28], *GSE6891* [53] and *GSE12417* [54] for expression, The Cancer Genome Atlas (TCGA) [50] for methylation). Briefly, gene expression data were obtained using Affymetrix Human Genome 133 plus 2.0 and U133A Gene Chips. All the designs and quality control for microarray experiment were according to the standard Affymetrix protocols. Expression data for microRNA were from TCGA obtained using whole-genome high-throughput sequencing, which provided 79 CN-AML patients [50]. In addition, genome-wide methylation levels in these patients were determined using Illumina

450K chips [50]. Patients with *RUNXI* expression values above the median of all patients were classified as having *RUNXI*^{high}, and the others were considered to have *RUNXI*^{low}. Levels of *ERG*, *BAALC*, *LEF1*, *MNI*, *WT1*, *DNMT3B*, *TCF4*, *MIR155HG*, *ITPR2* and *MAPKBPI* expression were also determined from the microarray data.

Statistical analyses

The time from the date of diagnosis to death due to any cause defined OS, and the time from the date of diagnosis to removal from the study due to the absence of complete remission, relapse or death defined EFS. Because we found that *RUNXI* expression is normally distributed, a distribution of the cohort based on the highest 50% (*RUNXI*^{high}) and the lowest 50% *RUNXI* expression (*RUNXI*^{low}) was used for further analysis (Supplementary Figure 5). The Kaplan-Meier method was then used to estimate the association between *RUNXI* expression and the OS and EFS, which were further validated using the log-rank test. To investigate the associations between *RUNXI* expression levels and clinical, molecular characteristics, the Fisher exact and Wilcoxon rank-sum tests were used for hypothesis testing with categorical and continuous variables, respectively. In addition, multivariable Cox proportional hazard models were used to study how *RUNXI* expression levels were associated with OS and EFS in the presence of other known risk factors. With the two groups divided based on *RUNXI* expression levels, Student's *t*-test and multiple hypothesis correction (False Discovery Rate, FDR) was used to identify differences in gene/microRNA expression and DNA methylation profiles. The statistical cutoff values were an absolute fold-change (FC) ≥ 1.5 and an adjusted *P*-value ≤ 0.05 . All analyses were performed using the R 3.1.1 software packages.

ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China (81500118, 61501519, 81172245)

Authors' contribution

L. Fu and L. Tian designed the study and wrote the manuscript, H.P. Fu, K.M. Xu, K. Hu and J. Wang performed statistical analyses, J.J. Wang and H.M. Jing analyzed the data, J.L. Shi and X.Y. Ke coordinated the study over the entire time. All authors approved the final manuscript.

CONFLICTS OF INTEREST

The authors report no potential conflicts of interest.

REFERENCES

1. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood reviews. 2004; 18:115–136. doi: 10.1016/S0268-960X(03)00040-7.
2. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007; 109:431–448. doi: 10.1182/blood-2006-06-001149.
3. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2011; 117:1121–1129. doi: 10.1182/blood-2010-09-191312.
4. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A, Bullinger L, Frohling S, Dohner H. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005; 106:3740–3746. doi: 10.1182/blood-2005-05-2164.
5. Li HY, Deng DH, Huang Y, Ye FH, Huang LL, Xiao Q, Zhang B, Ye BB, Lai YR, Mo ZN, Liu ZF. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis. European journal of haematology. 2015; 94:439–48. doi: 10.1111/ejh.12450.
6. Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, Verma D, Kantarjian H, Borthakur G. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011; 117:2145–2155. doi: 10.1002/cncr.25670.
7. Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, et al. *RUNXI* mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. Journal of clinical oncology. 2012; 30:3109–3118. doi: 10.1200/JCO.2011.40.6652.
8. Lyu X, Xin Y, Mi R, Ding J, Wang X, Hu J, Fan R, Wei X, Song Y, Zhao RY. Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. PloS one. 2014; 9:e92470. doi: 10.1371/journal.pone.0092470.
9. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, et al. *BAALC* and *ERG* expression levels are associated with outcome and distinct gene and microRNA expression

- profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Blood*. 2010; 116:5660–5669. doi: 10.1182/blood-2010-06-290536.
10. Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrozek K, Maharry K, Becker H, Metzeler KH, Whitman SP, Wu YZ, Powell BL, Baer MR, Kolitz JE, et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. *Blood*. 2011; 118:4188–4198. doi: 10.1182/blood-2011-06-357764.
 11. Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, et al. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. *Leukemia*. 2015; 29:567–575. doi: 10.1038/leu.2014.267.
 12. In 't Hout FE, van der Reijden BA, Monteferrario D, Jansen JH, Huls G. High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisions. *Haematologica*. 2014; 99:e257–259. doi: 10.3324/haematol.2014.110437.
 13. Shi JL, Fu L, Wang WD. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia. *Oncotarget*. 2015; 6:5299–5309. doi: 10.18632/oncotarget.3024.
 14. Fu L, Shi J, Hu K, Wang J, Wang W, Ke X. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia. *Oncotarget*. 2015; 6:8144–8154. doi: 10.18632/oncotarget.3519.
 15. Metzeler KH, Heilmeier B, Edmaier KE, Rawat VP, Dufour A, Dohner K, Feuring-Buske M, Braess J, Spiekermann K, Buchner T, Sauerland MC, Dohner H, Hiddemann W, et al. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. *Blood*. 2012; 120:2118–2126. doi: 10.1182/blood-2012-02-411827.
 16. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. *Journal of clinical oncology*. 2013; 31:2086–2093. doi: 10.1200/JCO.2012.45.6228.
 17. Shi Jinlong, Fu Lin, Li Yonghui, Yu Li, Weidong W. Identification of let-7a-2-3p or/and miR-188-5p as Prognostic Biomarkers in Cytogenetically Normal Acute Myeloid Leukemia. *PLOS One*. 2015 3;10:e0118099. doi: 10.1371/journal.pone.0118099.
 18. Lam K, Zhang DE. RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. *Front Biosci (Landmark Ed)*. 2012; 17:1120–1139. doi: 10.2741/3977.
 19. Ge T, Yin M, Yang M, Liu T, Lou G. MicroRNA-302b Suppresses Human Epithelial Ovarian Cancer Cell Growth by Targeting RUNX1. *Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2014; 34:2209–2220. doi: 10.1159/000369664.
 20. Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. *Oncogene*. 2004; 23:4255–4262. doi: 10.1038/sj.onc.1207727.
 21. Ferrari N, Mohammed ZM, Nixon C, Mason SM, Mallon E, McMillan DC, Morris JS, Cameron ER, Edwards J, Blyth K. Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. *PloS one*. 2014; 9:e100759. doi: 10.1371/journal.pone.0100759.
 22. Silva FP, Morolli B, Storlazzi CT, Anelli L, Wessels H, Bezrookove V, Kluin-Nelemans HC, Giphart-Gassler M. Identification of RUNX1/AML1 as a classical tumor suppressor gene. *Oncogene*. 2003; 22:538–547. doi: 10.1038/sj.onc.1206141.
 23. Ben-Ami O, Friedman D, Leshkowitz D, Goldenberg D, Orlovsky K, Pencovich N, Lotem J, Tanay A, Groner Y. Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. *Cell reports*. 2013; 4:1131–1143. doi: 10.1016/j.celrep.2013.08.020.
 24. Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. *The Journal of clinical investigation*. 2013; 123:3876–3888. doi: 10.1172/JCI68557.
 25. Goyama S, Huang G, Kurokawa M, Mulloy JC. Posttranslational modifications of RUNX1 as potential anticancer targets. *Oncogene*. 2015; 34:3483–92. doi: 10.1038/onc.2014.305.
 26. Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, Biswas D, Roeder RG, Allis CD, Melnick A, de Bruijn MF, Milne TA. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. *Cell reports*. 2013; 3:116–127. doi: 10.1016/j.celrep.2012.12.016.
 27. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. *The New England journal of medicine*. 2004; 350:1617–1628. doi: 10.1056/NEJMoa040465.
 28. Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogossova-Agadjanyan EL, Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery D, Wood B, Heimfeld S, Radich JP. Identification of genes with abnormal expression changes in acute myeloid leukemia. *Genes, chromosomes & cancer*. 2008; 47:8–20. doi: 10.1002/gcc.20500.

29. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. *Nature reviews Cancer*. 2010; 10:361–371. doi: 10.1038/nrc2826.
30. Toren A, Bielora B, Jacob-Hirsch J, Fisher T, Kreiser D, Moran O, Zeligson S, Givol D, Yitzhaky A, Itskovitz-Eldor J, Kventsel I, Rosenthal E, Amariglio N, et al. CD133-positive hematopoietic stem cell “stemness” genes contain many genes mutated or abnormally expressed in leukemia. *Stem Cells*. 2005; 23:1142–1153. doi: 10.1634/stemcells.2004-0317.
31. Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. *Leukemia & lymphoma*. 2014; 55:2817–2821. doi: 10.3109/10428194.2014.893305.
32. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. *Molecular cancer*. 2005; 4:18. doi: 10.1186/1476-4598-4-18.
33. Santos PM, Borghesi L. Molecular resolution of the B cell landscape. *Current opinion in immunology*. 2011; 23:163–170. doi: 10.1016/j.coi.2010.11.014.
34. Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, Yeo EL, Schuh AC, Sutherland DR. CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. *Experimental hematology*. 1999; 27:1282–1294. doi: 10.1016/S0301-472X(99)00071-5.
35. Liang S, Gong F, Zhao X, Wang X, Shen G, Xu Y, Yang H, Ruan X, Wei Y. Prokaryotic expression, purification of a new tumor-relative protein FAM92A1-289 and its characterization in renal cell carcinoma. *Cancer letters*. 2009; 276:81–87. doi: 10.1016/j.canlet.2008.10.043.
36. Kuo HY, Huang YS, Tseng CH, Chen YC, Chang YW, Shih HM, Wu CW. PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2. *Cell Cycle*. 2014; 13:3132–3142. doi: 10.4161/15384101.2014.949212.
37. Gerrits A, Walasek MA, Olthof S, Weersing E, Ritsema M, Zwart E, van Os R, Bystrykh LV, de Haan G. Genetic screen identifies microRNA cluster 99b/let-7e/125a as a regulator of primitive hematopoietic cells. *Blood*. 2012; 119:377–387. doi: 10.1182/blood-2011-01-331686.
38. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Journal of clinical oncology*. 2010; 28:2348–2355. doi: 10.1200/JCO.2009.27.3730.
39. Havelange V, Stauffer N, Heaphy CC, Volinia S, Andreeff M, Marcucci G, Croce CM, Garzon R. Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. *Cancer*. 2011; 117:4696–4706. doi: 10.1002/cncr.26096.
40. Lu D, Davis MP, Abreu-Goodger C, Wang W, Campos LS, Siede J, Vigorito E, Skarnes WC, Dunham I, Enright AJ, Liu P. MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs. *PLoS one*. 2012; 7:e40938. doi: 10.1371/journal.pone.0040938.
41. Li Y, Vecchiarelli-Federico LM, Li YJ, Egan SE, Spaner D, Hough MR, Ben-David Y. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. *Blood*. 2012; 119:4486–4498. doi: 10.1182/blood-2011-09-378687.
42. Gao XN, Lin J, Li YH, Gao L, Wang XR, Wang W, Kang HY, Yan GT, Wang LL, Yu L. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. *Oncogene*. 2011; 30:3416–3428. doi: 10.1038/ncr.2011.62.
43. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, Bozzoni I. A microcircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. *Cell*. 2005; 123:819–831. doi: 10.1016/j.cell.2005.09.023.
44. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder H, Calin GA, Liu CG, Andreeff M, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. *Oncogene*. 2007; 26:4148–4157. doi: 10.1038/sj.onc.1210186.
45. Sun SM, Rockova V, Bullinger L, Dijkstra MK, Dohner H, Lowenberg B, Jongen-Lavrencic M. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. *Leukemia*. 2013; 27:100–106. doi: 10.1038/leu.2012.158.
46. Esteller M, Fraga MF, Paz MF, Campo E, Colomer D, Novo FJ, Calasanz MJ, Galm O, Guo M, Benitez J, Herman JG. Cancer epigenetics and methylation. *Science*. 2002; 297:1807–1808; discussion 1807–1808. doi: 10.1126/science.297.5588.1807d.
47. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene body methylation can alter gene expression and is a therapeutic target in cancer. *Cancer cell*. 2014; 26:577–590. doi: 10.1016/j.ccr.2014.07.028.
48. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Grealley JM, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. *Cancer cell*. 2010; 17:13–27. doi: 10.1016/j.ccr.2009.11.020.
49. Alvarez S, Suela J, Valencia A, Fernandez A, Wunderlich M, Agirre X, Prosper F, Martin-Subero JI, Maiques A, Acquadro F, Rodriguez Perales S, Calasanz MJ, Roman-Gomez J, et al. DNA methylation profiles and their

- relationship with cytogenetic status in adult acute myeloid leukemia. *PloS one*. 2010; 5:e12197. doi: 10.1371/journal.pone.0012197.
50. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *The New England journal of medicine*. 2013; 368:2059–2074. doi: 10.1056/NEJMoa1301689
 51. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102:15545–15550. doi: 10.1073/pnas.0506580102
 52. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. *Oncogene*. 2004; 23:4284–4296. doi: 10.1038/sj.onc.1207779.
 53. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, Lowenberg B, Delwel R, Valk PJ. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. *Haematologica*. 2009; 94:131–134. doi: 10.3324/haematol.13299.
 54. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. *Blood*. 2008; 112:4193–4201. doi: 10.1182/blood-2008-02-134411.